The role of endometrial and embryonic integrins during implantation remains unresolved although work in animal models and in humans supports their involvement in this process. Temporal and spatial distribution of the ␣ v ␤ 3 integrin on both embryo and endometrium in women and mice coincides with the time of initial attachment during implantation. In mice, the endometrial and embryonic ␣ v ␤ 3 integrin is present at the time of implantation, as shown by reverse transcription-polymerase chain reaction and immunohistochemistry. In situ hybridization demonstrates the presence of the ␣ v ␤ 3 integrin on the subluminal stromal cells of the uterus. Functional blockade of this integrin on the day of implantation by intrauterine injection of neutralizing monoclonal antibodies against ␣ v or ␤ 3 integrin subunits, arg-gly-asp (RGD)-containing peptides, or of the disintegrin echistatin, reduced the number of implantation sites compared to controls receiving BSA. These studies demonstrate that, like the human, the murine ␣ v ␤ 3 integrin is expressed at the time of implantation in the endometrium and on the blastocyst, and may play a critical role in the cascade of events leading to successful implantation.
INTRODUCTION
Integrins are heterodimeric glycoproteins that are present on the surface of essentially all cells [1] . This class of cell adhesion molecules has been described in both embryo [2, 3] and endometrium [4] [5] [6] [7] at the time of implantation in the mouse and human. The programmatic expression of integrins in the placenta [8] [9] [10] and decidua [6, 11] extends the involvement of integrins into the later stages of implantation as well. Interest in the ␣ v ␤ 3 integrin has increased as a result of a number of earlier studies that correlate its expression with the window of implantation [6] , and its absence with certain types of infertility including luteal phase defect [4] , endometriosis [12] , hydrosalpinx [13] , and unexplained infertility [14] . Recent studies by Simón et al. have demonstrated that embryonic signaling may stimulate the expression of this integrin in the mouse [15] and human [16] endometrium as well.
Rodents appear to be excellent models for studying im- plantation and the role of cytokines, growth factors, and other factors during implantation. Integrin expression has been shown to be regulated during the estrous cycle in rats [17, 18] , and several factors have been shown to be essential for normal implantation in the mouse and rat [19] [20] [21] [22] [23] . Implantation in the mouse has been shown to involve extracellular matrix and specifically the three amino-acid peptide sequence, arg-gly-asp (RGD) [24] [25] [26] [27] [28] . In these studies, RGD has been shown to block trophoblast attachment and outgrowth both in vivo and in vitro. As this amino acid combination forms the ligand recognition sequence for the ␣ v ␤ 3 integrin, we have examined the expression of this integrin during early pregnancy in the mouse, and reported a temporal expression that is similar to that of leukemia inhibitory factor (LIF) [18] . In the present study, we expand on these findings by neutralization of this integrin during the time of implantation in the mouse model.
MATERIALS AND METHODS

Animals
Virgin 6-to 8-wk-old female CD1 mice (Charles River Laboratories, Raleigh, NC) were housed in the animal care facility in rooms with a controlled light schedule (14L:10D) and controlled temperature range (22-24ЊC), and were fed ad libitum. Females were bred with CD1 males and checked the following morning for vaginal plugs. The day of vaginal plug was recorded as Day 1 of pregnancy.
Immunohistochemistry
Embryos were obtained from 3 female mice after i.p. injection of 7.5 IU eCG. After 48 h, the mice received an i.p. injection of 7.5 IU hCG and were mated. The mice were killed on the morning of Day 4, and embryos were harvested by laparotomy and flushing of the uterine horns. Immunohistochemistry was performed using biotin-labeled ␣ v specific (biotinylated anti-mouse CD51; PharMingen, San Diego, CA) or ␤ 3 specific antibodies (fluorescein isothiocyanate-labeled anti-mouse CD61; PharMingen). The embryos were placed in Biocoat Insert Controls (Becton Dickinson, Franklin Lakes, NJ) during the entire staining process. Embryos were fixed with 2% paraformaldehyde in PBS pH 7.2 with 10% sucrose for 15 min and then rinsed two times with PBS. Embryos were treated with 2% hamster serum in PBS for 30 min to block nonspecific staining, then placed in primary antibody overnight at 4ЊC (1:10 dilution for ␣ v or ␤ 3 in 1% hamster serum). The embryos were then rinsed twice with PBS and incubated with avidinTexas Red (Vector, Burlingame, CA; 1:200 dilution in PBS) for 30 min at room temperature (RT). The embryos were rinsed twice with PBS and then fixed a final time with 2% paraformaldehyde in PBS with 10% sucrose and again rinsed twice with PBS. The Biocoat Insert Control filters were cut out of the plastic containers and placed on a slide, coverslips were placed, and the slides were viewed under a fluorescence microscope. Uteri from Day 4 pregnant mice were snap-frozen in liquid nitrogen, and immunohistochemistry was performed on cross sections for ␣ v and ␤ 3 integrin subunits.
Reverse Transcription (RT)-Polymerase Chain Reaction (PCR) Assays
Poly(A) ϩ RNA was isolated from mouse embryos and uteri using the Micro-Fast kit (Invitrogen, Carlsbad, CA), from which single-strand cDNA was synthesized using the cDNA cycle kit (Invitrogen). One half microliter of cDNA was used per 50 l PCR reaction. The reaction mixture contained 100 mM Tris-HCL pH 9.0; 500 mM KCL; 1% Triton X-100; 2 mM MgCl 2 ; 0.2 mM each of dATP, dGTP, dCTP, dTTP; and 0.5 U Taq DNA polymerase (Promega, Madison, WI). The primers used for PCR are shown in Table 1 along with the expected size of the product based on primer location. PCR amplification was performed by a three-step process: 1) initial denaturation at 95ЊC, for 10 min; 2) annealing at 60ЊC for 2 min and extension at 72ЊC for 3 min; and 3) final extension at 72ЊC for 10 min. The amplified products were separated on 1% agarose gels using a 1-kilobase (kb) DNA ladder (Promega) for size comparison. The cDNA probes for ␣ v and ␤ 3 subunits were generated by RT-PCR using primers previously described [18] (Table 1) .
In Situ Hybridization
A hybridization-digoxigenin staining protocol was used according to the method of Schaeren-Wiemers and GerfinMoser [29] . Briefly, uteri from pregnant CD-1 females were excised, placed directly in OCT Tissue Tek (Bayer Corp., Elkhart, IN), frozen on dry ice, sectioned in a cryostat at 10-m-thick sections, and collected onto ribonuclease (RNase)-free Fisherbrand Plus glass microscope slides (Fisher Scientific, Pittsburgh, PA). Slides were air-dried for 20 min to 3 h. Sections were fixed for 10 min at 25ЊC in 4% paraformaldehyde in PBS, washed 3 times in PBS, and acetylated using a solution of acetic anhydride. Hybridization buffer (50% formamide, 5-strength SSC [single-strength SSC is 0.15 M sodium chloride, 0.015 M sodium citrate], 5-strength Denhardt's solution, 250 g/ml yeast RNA, and 500 g/ml herring sperm DNA) was placed on each section and incubated for 2 h at RT in a 5-strength SSC humidified chamber. The hybridization buffer was removed and replaced with fresh hybridization buffer containing 200-400 ng/ml of digoxigenin-labeled sense and antisense RNA probes (see above). Sections were covered with a coverslip, and samples were incubated in humidified 5-strength SSC, 50% formamide at 72ЊC. After hybridization, the coverslips were removed, and the specimens were transferred first into 0.2-strength SSC at 72ЊC for 1 h, and then into 0.2-strength SSC at 25ЊC for 5 min to remove unbound probe. Slides were placed in a blocking buffer (0.1 M Tris pH 7.6, 0.15 M NaCl containing 1% heat-inactivated goat serum) for 1 h at RT in a humidified chamber. After the blocking buffer was poured off, anti-digoxigenin antibody (1:5000 dilution; Fab fragment conjugated to alkaline phosphatase; Boehringer Mannheim, Indianapolis, IN) was added, and samples were incubated at 4ЊC overnight. After extensive washing in 0.1 M Tris pH 9.4, 0.1 M NaCl, and 50 mM MgCl 2 to reduce background, the color reaction was carried out for 6 h to 3 days at RT using 4-nitro blue tetrazolium chloride (NBT; Boehringer Mannheim), 5-bromo-4-chloro-3-indolyl-phosphate (BCIP; Boehringer Mannheim), and levamisole (Sigma Chemical Co., St. Louis, MO) in dimethylformamide. Samples were mounted with glass coverslips using Aquamount (Baxter Scientific, Westchester, PA).
Digoxigenin-labeled RNA sense and antisense probes (ϳ10 g) were prepared by mixing 10-strength transcription buffer (Promega), 0.2 M dithiothreitol, digoxigenin nucleotide mix (Boehringer Mannheim; 10 mM GTP, 10 mM ATP, 10 mM CTP, 6.5 mM UTP, 3.5 mM digoxigenin-UTP, pH 8.0), 1 g of linearized ␤ 3 integrin cDNA, placental RNase inhibitor (100 U/ml), and SP6, T7, or T3 RNA polymerase (10 U/ml; Promega). The synthesis of probe was monitored by electrophoresis of an aliquot through a 1% agarose Tris-borate-EDTA gel (with 0.5 mg/ml ethidium bromide). An RNA band ϳ10-fold more intense than the plasmid band indicated the successful synthesis of the probe. Deoxyribonuclease (RNase-free; Promega) was added to the digoxigenin RNA synthesized probes and incubated for 15 min at 37ЊC. A solution containing 50 mM Tris, 1 mM EDTA pH 8.0, 10 l 4 M LiCl, and 300 l ethanol was added to the probes, mixed, and maintained at Ϫ20ЊC for 30 min. RNA was pelleted and dried.
Function Blocking Studies
To determine whether the ␣ v ␤ 3 integrin may play a role in implantation, we investigated the effect of blocking this integrin using intrauterine injection of various bioactive compounds on the day of implantation. After coitus and documentation of a vaginal plug, each female underwent midventral laparotomy on Day 4 of pregnancy between 0900 and 1100 h. The right horn of each mouse was fixed with forceps, and the needle was very slowly introduced as close as possible to the cervix into the uterine horn. One of the following substances was injected into the right horn of each animal: the ␣ v -specific neutralizing monoclonal antibody (H9.1C; PharMingen; 0.2 or 4 g in 100 l; n ϭ 10), the neutralizing antibody against ␤ 3 subunit (2C9.G2; PharMingen; 5 g in 100 l; n ϭ 3), echistatin (Sigma; 0.1 or 0.5 g in 100 l; n ϭ 10), RGD-containing hexapeptides (GRGDSP; Gibco, Grand Island, NY; 200-500 g in 100 l in 0.9% saline; n ϭ 11), and a non-RGD sequence (GRGESP; Gibco; 500 g in 100 l in 0.9% saline; n ϭ 4). The total amount of each injection was infused slowly over 3 min, injected from the cervix toward the uterotubal junction. Each animal served as her own control, with the left uterine horn receiving 100 l of 0.9% saline. As controls, some pregnant females received 500 g BSA in 100 l of 0.9% saline into the right horn (n ϭ 5). On Day 7 of pregnancy, all animals were killed, the uteri were removed by laparotomy, and the number of implants was counted in each uterine horn.
Statistical Comparisons
The numbers of implantation sites were compared between groups. Data are presented as percentage of control, comparing the number of implantation sites in the left (con- . Positive bands were noted for both ␣ v and ␤ 3 subunits using specific oligomer primers with the expected size (see Table 1 ). Similar studies were performed on isolated endometrium from the Day 4 pregnant mice (lower panel). Again, both subunits were present on cycle Day 4 by RT-PCR.
FIG. 2.
Photomicrographs of immunofluorescence for the ␣ v ␤ 3 integrin in the mouse blastocyst (A) and endometrium (B) on the day of implantation (Day 4). ϫ200 (published at 88%). Note that the ␣ v ␤ 3 immunostaining is present on the outer portion of the embryo, and on the subliminal border with the luminal epithelium in the endometrium. trol) horn to the right (treatment) horn. Overall statistical comparison was made of the number of implantation sites in the treated horn, between groups, using ANOVA with Scheffe's correction for multiple comparisons.
RESULTS
The presence of ␣ v and ␤ 3 subunits was examined first with RT-PCR, as shown in Figure 1 . Both subunits were present on mouse blastocysts (upper panel) and on the endometrium of mice at the time of implantation (lower panel). As seen in Figure 2 , the localization of expression of the ␣ v ␤ 3 integrin was shown in both blastocyst (A) and endometrium (B), using the ␤ 3 specific antibody, 2C9.G2. The pattern was similar using both ␣ v and ␤ 3 specific monoclonal antibodies. While the embryo was uniformly positive, the endometrium expressed this integrin in the subluminal stroma as previously reported [15, 18] . This pattern of expression was also shown by in situ hybridization (Figure 3 ), using the specific ␤ 3 antisense strand, with specific staining localized in the stromal cells immediately below the luminal surface. Only nonspecific labeling was seen using the ␤ 3 sense probe.
To investigate the potential role of ␣ v ␤ 3 on implantation using the mouse model, several reagents that specifically block the ability of this integrin to bind ligand were injected into the uterine horn at the time of initial attachment on the morning of Day 4 of pregnancy (Fig. 4A) . Injections of BSA (bar 1) were compared to immunologic neutralization with ␣ v specific monoclonal antibody (H9.2B8; bar 2) or ␤ 3 specific antibody (2C9.G2; bar 3); the snake venom disintegrin, echistatin (bar 4), which specifically inactivates the ␣ v ␤ 3 integrin; or competitive inhibition with peptides containing the RGD sequence (GRGDSP; bar 5). As a secondary control, some animals received the non-RGD-containing peptides (GRGESP; bar 6). In each case the contralateral horn served as an internal control. As shown in Figure 4C , mouse uteri from controls receiving BSA contained 6-8 implanted embryos in the injected right uterine horn similar to the left control horn. In a typical experiment, when one uterine horn received injection of substances that neutralize or block ␣ v ␤ 3 integrin activity, there was a significant reduction in the number of implantation sites in that experimental horn (injection of RDG peptides into the right horn; Fig. 4B ). Normal or near normal implantation rates were seen in the saline-injected left uterine horn. Using ANOVA with Scheffe's correction, there was an overall significant difference in the number of implantation sites between groups (P Ͻ 0.0001). RGD (bar 4), and echistatin (bar 5) resulted in significant reduction in the number of implants compared to those in the non-injected horn (P ϭ 0.024 and 0.02, respectively). Injection with the monoclonal antibody against the ␣ v subunit, H9.2B8 (bar 2) and the anti-␤ 3 antibody (2C9.G2; bar 3) reduced the number of FIG. 3 . In situ hybridization of Day 4 uteri using sense and antisense probes for ␤ 3 . Nonspecific staining was observed with the sense strand. Using antisense ␤ 3 probe, the strongest signal was detected in the stromal compartment, localized near the luminal epithelium. ϫ10.
FIG. 5.
Effect of concentration of various reagents on the number of implantation sites in the mouse model. One of the following substances was injected into the right horn of each animal: the ␣ v -specific neutralizing monoclonal antibody (H9.1C; Pharmingen; 0.2 or 4 g in 100 l; n ϭ 3 and 5, respectively), the RGD-containing hexapeptides (GRGDSP; Gibco; 200-500 g in 100 l in 0.9% saline; n ϭ 3 and 7, respectively), and echistatin (Sigma; 0.1 or 0.5 g in 100 l; n ϭ 5 and 5, respectively). Each was compared to injection of BSA as a control (n ϭ 5). The higher dose of each was significantly different from the control BSA horn (all Ͻ 0.01). Although each of the higher doses had a lower number of implantation sites present, only the RDG group reached statistical significance (P Ͻ 0.04) compared to the lower dose administered. Pairings that are significantly different based on ANOVA with Scheffe's correction are represented by connecting bars at the top of the graph. anti-␤ 3 , 2C9.G2, 0.5 g/ml (n ϭ 3); 4) echistatin, 0.5 g/ml (n ϭ 4); 5) RDG peptide, 500 g/ml (n ϭ 7); and 6) non-RGD peptides, 500 g/ml (n ϭ 4). Both echistatin and RDG significantly reduced the implantation rate compared to BSA injections (P ϭ 0.024 and 0.02, respectively [bars 4 and 5]). Example of a uterus injected with RDG peptides is shown in B; a BSA control is shown in C.
implantation sites, but this did not reach significance (P ϭ 0.07).
The effect of these reagents was found to be dose-dependent (Fig. 5) . Comparison of 0.2 g/ml of the anti-␣ v antibody H9.1C to a higher concentration of 4 g/ml showed little difference. Marginal differences were noted in implantation site numbers using different concentrations of echistatin (0.1 vs. 0.5 g/ml; P ϭ 0.0.1), and a significant difference was noted using high vs. low concentrations of RDG peptide (20 vs. 50 g/ml; P Ͻ 0.04).
The higher dose of each reagent resulted in a significant reduction in the number of implantation sites compared to the BSA control sites (all Ͻ 0.01). It is likely that the ''low'' concentration of the neutralizing antibody was already saturating, and this prevented us from observing a true dose response using that chosen dose of the anti-␣ v antibody H9.1C.
DISCUSSION
Our understanding of the mechanism of implantation continues to expand as new proteins are discovered that are temporally and spatially associated with embryo-uterine attachment. The discovery of cycle-dependent integrins in the human endometrial epithelium and stroma that frame the window of implantation [4] [5] [6] has raised expectations that these molecules are somehow involved in the cascade of events leading to successful pregnancy. Studies on the early embryo [2, 3] and placenta [8] [9] [10] also demonstrate a highly orchestrated pattern of integrin expression in the trophoblast of early pregnancy. Recent evidence demonstrates that integrins are regulated in the uterus of rodents [16, 18] . It also appears that an active dialogue exists between embryo and endometrium that further modulates integrin expression [15] . The ␣ v ␤ 3 integrin appears to be specifically present in the endometrium during the window of implantation in both humans and mice. Ligand binding to ␣ v ␤ 3 is dependent on the three-amino acid sequence arg-gly-asp (RGD), which is involved in embryo attachment and outgrowth in vivo [24] [25] [26] [27] . In addition, studies have been reported to suggest the involvement of RGD in implantation in vivo [28] .
Studies from other species suggest that RGD and integrin expression at the time of implantation may define the period of receptivity. In the human, the ␣ v ␤ 3 , ␣ 4 ␤ 1 , and ␣ 1 ␤ 1 integrins are all co-expressed during the putative window of implantation on Days 20-24 [6] . Integrin and extracellular matrix expression has also been examined in several large animal models. In the sheep, ␣ v ␤ 3 and its putative ligand osteopontin are both expressed during the periimplantation period [30] . Porcine endometrium has been shown to express a different complement of integrins, including regulation of ␣ 5 ␤ 1 integrin [31] . The baboon also expresses the ␣ v ␤ 3 integrin, but the timing of its expression is delayed [32] . These differences in RGD-dependent integrin expression may ultimately be shown to contribute to the differences noted between temporal and spatial patterns of placental invasion that exists between these species.
Competitive inhibition of the ␣ v ␤ 3 integrin binding site by RGD-containing peptides or neutralization with disintegrins and monoclonal antibodies significantly reduced the number of implantation sites observed in the treated uterine horn compared to the untreated horn and to controls receiving a non-RGD peptide or BSA. Not all evidence supports a critical role of the ␣ v ␤ 3 vitronectin receptor in implantation. The mouse null mutant for ␣ v ␤ 3 is fertile and undergoes implantation, even though the embryos have reduced survival and placental defects [33] . This finding in the null mutant mouse may represent developmental compensation, given the presence of alternative ␤ subunits, such as ␤ 5 , which can also pair with ␣ v . Glanzmann's thromboasthenia patients who have a mutation in the ␤ 3 subunit of the ␣ IIb /␤ 3 platelet integrin have platelet dysfunction but remain fertile. The bones of such patients are also normal. Since osteoclasts normally employ the ␣ v ␤ 3 for osteoclastmediated remodeling, this finding suggests that other ␣ v integrins (␣ v ␤ 5 or ␣ v ␤ 6 ) can compensate for and restore normal osteoclast function when the ␤ 3 integrin is missing or dysfunctional.
In light of these controversies, our findings should be interpreted with caution. Injection of function-perturbing agents could interfere with implantation at many levels. Embryonic integrin function may be the target of our intervention, disrupting embryo survival or function. It was recently shown that RGD peptides block mouse embryo attachment to human endometrial stromal cells [34] . Our studies and those of others have shown that the ␤ 3 subunit is present on the outer surface of the mouse [3] and human [2] blastocyst. Cheresh and coworkers [35] have demonstrated that ␣ v ␤ 3 integrin is critical for angiogenesis. Neutralization of this integrin at the time of implantation could reduce embryo survival by preventing new vessel formation at the site of implantation and could account for the reduced number of implantation sites following injection of integrin neutralization agents.
In summary, the expression of embryonic and endometrial ␣ v ␤ 3 integrin during the window of implantation in the mouse suggests that this molecule does play a role in the implantation process. As previously shown both in vitro and in vivo, RGD peptides are competitive inhibitors of certain integrins and may interfere with implantation-mediated events. Our study further supports a role for ␣ v ␤ 3 integrin in this process and suggests a potentially critical function for this integrin in endometrial-embryo interactions. Targeting integrins may provide a new avenue for the development of contraceptive technologies, and the loss of this integrin in certain infertility states may signify the presence of implantation defects that reduce cycle fecundity in women.
